US equities |
MU $1,079.65 ▲+3.26% NVDA $236.49 ▼-1.15% SNDK $1,705.20 ▲+2.69% SPCX $166.52 ▼-3.14% AMD $642.20 ▼-1.11% TSLA $376.68 ▼-1.05% INTC $112.35 ▼-0.13% AAPL $336.94 ▲+0.99%
FinancialContent

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

24.48 +0.20 (+0.80%)
Delayed Quote Updated: 3:05 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗
Arcus (RCUS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Arcus Biosciences Inc (NYSE:RCUS) Reports Mixed Q4 2025 Results as Pipeline Strategy Pivots to Casdatifan ↗
Via Chartmill
News headline image
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
From Arcus Biosciences
Via Business Wire
News headline image
Analyst Expectations For Arcus Biosciences's Future ↗
 
Via Benzinga
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ ↗
Via Stocktwits
News headline image
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return ↗
Arcus Biosciences, a clinical-stage oncology innovator, reported significant insider selling as its stock capped a strong one-year return. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Arcus Biosciences
Via Business Wire
News headline image
Why Did Arcus Biosciences Stock Slump 10% Today? ↗
Arcus will stop testing a domvanalimab-based drug combination in upper gastrointestinal cancers after independent reviewers found the treatment did not improve survival. 
Via Stocktwits
News headline image
Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan ↗
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
From Arcus Biosciences
Via Business Wire
News headline image
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months ↗
Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy. 
Via Benzinga
News headline image
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment ↗
Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug. 
Via Investor's Business Daily
News headline image
Why Is Arcus Biosciences Stock Trading Higher On Monday? ↗
Arcus Biosciences reports casdatifan monotherapy data in renal cancer, showing a 35% response rate and median progression-free survival not yet reached. 
Via Benzinga
News headline image
Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation
From Arcus Biosciences
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >